







Comparison of Adalimumab originator and biosimilar formulations

This summary table includes information on the differences between the NHS contracted adalimumab products (PFS and PFP) that are likely to affect the choice of product for a patient or population. Refer to full product information for complete details on indications, stability and list of excipients.

	Humira® (AbbVie)	Amgevita (Amgen)	Hyrimoz (Sandoz)	Idacio (Fresenius Kabi)	Imraldi (Biogen)	Yuflyma (Celltrion)
Images of pack and device provided for 40mg pre-filled pens only						
Licensed Indications	All adalimumab biosimilar products (regardless of strength) are licensed for the same indications as Humira 40mg with one exception: Hyrimoz is not licensed for paediatric ulcerative colitis. Humira 20mg is licensed for paediatric indications and Humira 80mg is licensed for a selection of adult and paediatric indications.					
Concentration	40mg/0.4mL	40mg/0.8mL	40mg/0.8mL	40mg/0.8mL	40mg/0.8mL	40mg/0.4mL
Strengths: pre-filled SYRINGES	20mg, 40mg, 80mg	20mg, 40mg	20mg, 40mg	40mg	40mg	
Strengths: pre-filled PENS	40mg, 80mg	40mg	40mg	40mg	40mg	40mg, 80mg
Needle size (PFS and PFP)	29G	PFS: 29G PFP: 27G	27G	29G	29G	29G
Potential allergens	Polysorbate 80, mannitol	Polysorbate 80, latex, mannitol	Polysorbate 80, latex, mannitol	Polysorbate 80, mannitol	Polysorbate 20	Polysorbate 80
Citrate-containing	No	No	Yes	Yes	Yes	No
Stability at up to 25°C	14 days	14 days	21 days	28 days	28 days	30 days
Notes	PFS needle does not retract after administration					

PFP = pre-filled pen, PFS = pre-filled syringe